- Home
- CEV vs SLGL Comparison
CEV vs SLGL Comparison
Compare CEV & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | SLGL |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 69.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CEV | SLGL |
|---|---|---|
| Price | $10.40 | $38.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 19.6K | ★ 20.6K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.36 | ★ N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $8.83 | $4.02 |
| 52 Week High | $10.91 | $52.26 |
Technical Indicators
Market Signals| Indicator | CEV | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 57.37 |
| Support Level | $10.33 | $34.47 |
| Resistance Level | $10.62 | $45.47 |
| Average True Range (ATR) | 0.10 | 3.92 |
| MACD | -0.02 | 0.36 |
| Stochastic Oscillator | 31.03 | 67.17 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.